To hear about similar clinical trials, please enter your email below
Trial Title:
Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell Carcinoma
NCT ID:
NCT06565585
Condition:
Penile Cancer, Recurrent
Conditions: Official terms:
Carcinoma, Squamous Cell
Penile Neoplasms
Recurrence
Conditions: Keywords:
Penile cancer
Local recurrence
Organ-sparing surgery
Study type:
Observational
Overall status:
Enrolling by invitation
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Procedure
Intervention name:
Glans-sparing surgery
Description:
Patients who underwent glans-sparing surgery
Arm group label:
Low-risk Glans-sparing surgery patients
Summary:
The treatment paradigm for primary penile squamous cell carcinoma (PSCC) has increasingly
favored maximal organ preservation without compromising oncological outcomes. However,
the literature has often included heterogeneous patient cohorts and varied surgical
approaches, making it challenging to draw definitive conclusions about the impact of
local recurrence (LR) on survival.
Since the investigators recently published the results from a large, multicentric
international study on a homogeneous cohort of high-risk PSCC patients who were treated
with upfront complete glansectomy, the investigators have been demonstrating that local
recurrence after upfront glansectomy was strongly correlated with worse overall survival
and cancer-specific survival in this more homogeneous cohort, therefore challenging the
dogma that LR following organ-sparing surgery for PSCC does not affect survival outcomes
(Roussel et al., BJU Int 2021; DOI: 10.1111/bju.15297).
The investigators hypothesized that these findings were caused by an enrichment of higher
risk tumors in this cohort since solely glansectomy patients with a complete removal of
all the glandulopreputhial epithelium were included. Consequently, the hypothesis has
arisen that LR might not be a predictor of poorer survival outcomes in lower-risk tumors
who underwent glans-sparing surgery defined as circumcision, wide local excision, laser
ablation, glans resurfacing and partial glansectomy, and that previous findings
influencing the guidelines may be heavily influenced by the inclusion of large
proportions of low-risk tumors in rather heterogenous cohorts in terms of technical
approach.
Therefore, this study aims to explore whether LR similarly affects survival in lower-risk
tumors treated with glans-sparing techniques such as circumcision, wide local excision,
glans resurfacing, laser ablation, and partial glansectomy.
Detailed description:
Penile squamous cell carcinoma (PSCC) is a rare disease with a limited body of evidence
on which to base management decisions. The World Health Organization (WHO) has estimated
36,068 new cases of penile cancer in 2020, with an age-standardized incidence of 0.8 per
100,000 people worldwide. Traditionally performed partial or total penectomy have been
associated with significant comorbidity with respect to altered voiding, sexual function,
appearance, and psychological well-being.
In terms of treatment of the primary the European Association of Urology (EAU) guidelines
recommend performing complete tumor removal with as much organ preservation as possible,
without compromising oncological control. Organ-sparing surgery (OSS) encompasses a
plethora of surgical techniques including wide local excision, circumcision, glans
resurfacing, and partial or total glansectomy.
Consequently, penile-sparing approaches have been increasingly employed, with excellent
functional outcomes and significant improvements in patients' quality of life compared to
radical treatment. This trend towards OSS is based on the fact that, although patients
treated with penile preservation experience more local recurrence (LR) compared to
partial or total penectomy, the occurrence of LR did not compromise survival in several
previously studied cohorts with a heterogeneous patient population including both
high-risk and low-risk tumors.
However, the investigators recently published the results from a large, multicentric
international study on a homogeneous cohort of high-risk patients who were treated with
upfront complete glansectomy. It was found that LR after upfront glansectomy represents
an underlying aggressive disease course and was strongly correlated with worse overall
survival (HR 2.89, 95% CI 2.02-4.14, <0.001) and cancer-specific survival (HR 5.64, 95%
CI 3.45-9.22, P < 0.001) in this cohort, therefore challenging the dogma that LR
following OSS for PSCC does not affect survival outcomes. Multivariable Cox proportional
hazards regression analysis identified pT3 stage and high-grade disease as independent
predictors of LR.
The investigators hypothesized that these findings were caused by an enrichment of higher
risk tumors in our cohort, since solely glansectomy patients who undergo a complete
removal of all the glandulopreputhial epithelium were studied. Conversely, the
investigators would hypothesize that LR might not be a predictor of poorer survival
outcomes in lower risk tumors who undergo wide local excision, partial glansectomy, laser
ablation, circumcision or glans resurfacing. This would be the reason that previous,
heterogenous cohorts, including these techniques did not find an adverse effect of LR on
survival outcomes.
Therefore, the aim of this study is to study predictive pathological factors for LR as
well as the impact of LR on long-term survival outcomes solely in patients who are
treated with wide local excision, partial glansectomy, laser ablation, circumcision and
glans resurfacing, reflecting a lower risk OSS patient population, defined as
glans-sparing surgery.
Criteria for eligibility:
Study pop:
We will collect data from patients operated in high-volume penile cancer centers on in
the period from 1st of January 2000 to 1st of June 2023. All patients should have
undergone glans-sparing surgery.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Age over 18 years.
- Underwent low-risk OSS defined as: wide local excision, partial glansectomy, laser
ablation, circumcision, and glans resurfacing for PSCC
Exclusion Criteria:
- Underwent partial or total penectomy as primary surgery
- regional lymph node involvement at presentation (cN+ stage)
- metastates at presentation (cM+ stage)
Gender:
Male
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University hospitals Leuven
Address:
City:
Leuven
Zip:
3000
Country:
Belgium
Start date:
June 3, 2024
Completion date:
June 2025
Lead sponsor:
Agency:
Universitaire Ziekenhuizen KU Leuven
Agency class:
Other
Source:
Universitaire Ziekenhuizen KU Leuven
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06565585